Key result
Flosequinan increases exercise time by ~29% versus placebo in HF patients.
Why the study?
Different methods of assessing exercise capability in patients with heart failure provide varying measures of incapacity, necessitating evaluation of these methods.
How do different methods of measuring exercise capability compare in patients with heart failure before and after treatment with flosequinan?
Population
12 patients with heart failure
Comparison
Flosequinan treatment vs placebo
Design
Exercise testing with two treadmill protocols and corridor walk test
Follow-up
5 weeks
Authors
Loading...
Exercise tests yield inconsistent incapacity measures in heart failure; leaves open standardization before clinical or trial adoption.
How do different methods of measuring exercise capability compare in patients with heart failure before and after treatment with flosequinan?
Absolute Event Rate: 680% vs 526%
Different methods of assessing exercise capability in heart failure patients yield different measures of incapacity and respond differently to vasodilator therapy.
Cowley et al. (1991) studied Heart failure (n=12). Flosequinan vs. Placebo was evaluated on Exercise time on modified Bruce protocol (seconds). Flosequinan increased exercise time in heart failure patients from 526 s on placebo to 680 s after 5 weeks on the modified Bruce protocol, highlighting that different methods yield different measures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: